- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05242510
Evaluation of Exotropia After Patching the Eye or After Prism Adaptation (DESDEE)
April 1, 2025 updated by: Matthew Gearinger, University of Rochester
Divergence Excess/Simulated Divergence Excess Exotropia (DESDEE)
This study intends to determine the number and percent of subjects initially diagnosed with divergence excess exotropia which would be reclassified as simulated divergence excess exotropia if tested after 24 hours of monocular occlusion (patching) or after prism adaptation for the distance angle.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Kingston, Ontario, Canada
- Queen's University
-
-
-
-
-
Hyderabad, India
- LV Prasad Eye Institute
-
-
-
-
Central
-
Rishon LeZion, Central, Israel
- Shamir Medical Center
-
-
-
-
-
Milan, Italy
- University of Milan
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- University of California Los Angeles
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Harvard University
-
-
New York
-
Buffalo, New York, United States, 14209
- Ross Eye Institute
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed with divergence excess exotropia according to standard criteria (see Study Procedures for specifics)
- No prior strabismus surgery
- Able to cooperate with testing (by examiner determination)
- Neurologically normal except for strabismus (ADHD and autism spectrum are not exclusion criteria as long as the subject can cooperate for necessary testing)
- Not amblyopic at the time of enrollment (best-corrected visual acuity in both eyes of 20/40 or better)
- Under 18 years of age. There is no lower age limit as long as the subject can cooperate for the required testing.
- No diagnosis of dissociated vertical deviation
Exclusion Criteria:
- No diagnosis of divergence excess exotropia according to standard criteria (see Study Procedures for specifics)
- Prior strabismus surgery
- Unable to cooperate with testing (by examiner determination)
- Diagnosed with a neurological disorder (ADHD and autism spectrum are not exclusion criteria as long as the subject can cooperate for necessary testing)
- Best-corrected visual acuity in either eye worse than 20/40
- 18 years of age or older
- Diagnosed with dissociated vertical deviation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patching
|
The subject will occlude the non-dominant eye for 24 hours.
|
|
Experimental: Prism Adaptation
|
The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks.
• Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes.
At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia.
If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of participants reclassified as divergence excess exotropia
Time Frame: 2 weeks
|
Percentage of patients with distance and near exotropia measurements within 2.5 prism diopters on alternate prism and cover testing after 24 hours of patching or 7-14 days of fresnel prism use.
|
2 weeks
|
|
Percent of participants reclassified as simulated divergence excess exotropia
Time Frame: 2 weeks
|
Percentage of patients with distance and near exotropia measurements differing by more than 2.5 prism diopters on alternate prism and cover testing after 24 hours of patching or 7-14 days of fresnel prism use.
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 27, 2024
Primary Completion (Actual)
September 18, 2024
Study Completion (Actual)
September 18, 2024
Study Registration Dates
First Submitted
January 24, 2022
First Submitted That Met QC Criteria
February 4, 2022
First Posted (Actual)
February 16, 2022
Study Record Updates
Last Update Posted (Actual)
April 4, 2025
Last Update Submitted That Met QC Criteria
April 1, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00006849
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exotropia
-
Yonsei UniversityCompletedExotropia or Intermittent ExotropiaKorea, Republic of
-
Retina Foundation of the SouthwestRecruiting
-
Benha UniversityCompletedIntermittent ExotropiaEgypt
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Pediatric Eye Disease Investigator GroupCompleted
-
Cairo UniversityUnknownIntermittent Exotropia
-
Tehran University of Medical SciencesUnknownIntermittent Exotropia
-
Sun Yat-sen UniversityUnknownIntermittent ExotropiaChina
-
Samsung Medical CenterUnknown
-
Nunaps IncCompletedIntermittent ExotropiaSouth Korea
-
Retina Foundation of the SouthwestActive, not recruiting
Clinical Trials on Patching
-
City, University of LondonImperial College LondonCompleted
-
Washington University School of MedicineCompletedCentral Serous Retinopathy (CSR)United States
-
Minia UniversityRecruiting
-
Eye & ENT Hospital of Fudan UniversityFirst Affiliated Hospital of Fujian Medical University; Jiangsu Provincial... and other collaboratorsRecruiting
-
Eye & ENT Hospital of Fudan UniversityActive, not recruiting
-
The Hospital for Sick ChildrenCompleted
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Pediatric Eye Disease Investigator GroupWithdrawnRefractive Errors | Anisometropic Amblyopia
-
Retina Foundation of the SouthwestNational Eye Institute (NEI)Recruiting
-
NovaSightActive, not recruiting